WARNING: As this organisation lists one or more EP accredited lobbyists, it is highly improbable that its lobbying costs are lower than €10,000.
WARNING: The lobbying costs declared by this organisation are extraordinarily high and may therefore have been over-declared.
1,500,000€ - 1,749,000€
Lobbyists declared: 5.25 FTE (10)
WARNING: The number of full time equivalent lobbyists declared by this organisation are extraordinarily high and may therefore have been over-declared.
Lobbyists with EP accreditation: 6
Meetings with European Commission: 10
Lobbying costs over the years:
Registration on EU Transparency Register
Goals / Remit
GSK is a science-led global healthcare company.
Our purpose is to help people do more, feel better, live longer.
We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses (Pharmaceuticals, Vaccines and Consumer Healthcare), scientific and technical know-how and talented people.
Our Pharmaceutical business has a broad portfolio of innovative and established medicines. We currently focus on developing new medicines in respiratory and HIV/infectious diseases, oncology and immuno-inflammation; with discovery research exploring these and other areas.
The business is made up of innovative and established medicines and holds leading market positions in respiratory disease and HIV. In our Pharmaceuticals R&D organisation, almost 80% of research spending focuses on two current therapy areas: respiratory and HIV/infectious diseases; and two potential areas: oncology and immuno-inflammation.
Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. We deliver over two million vaccine doses per day to people living in over 160 countries.
The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta (US) site dedicated to smallpox vaccine production since 1882. Today, our vaccines continue to tackle some of the world’s most devastating diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza.
Our Vaccines business has a portfolio of more than 40 vaccines for every stage of life, helping to protect people against 22 diseases. We have a pipeline of 14 candidate vaccines in development. One third of our vaccines in development target diseases particularly prevalent in the developing world, including all three WHO infectious disease priorities: HIV, malaria and TB. Our other vaccines in development include vaccines for the treatment of COPD and prevention of Respiratory Syncytial Virus (RSV).
Our Consumer Healthcare business develops and markets consumer preferred and expert recommended brands in the Oral health, Pain relief, Respiratory, Nutrition/gastro-intestinal and Skin health categories.
We have a portfolio of loved and trusted brands that are underpinned by science including: Sensodyne, Parodontax, Poligrip, Voltaren, Panadol, Otrivin and Theraflu.
We have a significant global presence with commercial operations in more than 150 countries, a network of 86 manufacturing sites in 36 countries and large R&D centres in the UK, USA, Spain, Belgium and China.
We follow EU initiatives, policies and legislative files related to our Pharmaceuticals, Vaccines and Consumer Healthcare businesses. This includes topics such as R&D and clinical trials, antimicrobial resistance, data protection, pharmaceutical legislation, medical devices, trade & IP, environment, smoking cessation.
Great West Road, 980
Brentford, Middlesex TW8 9GS,
Tel: 44 20 8047 5000
37 Square de Meeûs
Tel: 32 27917600
Lobbyists with EP accreditation
The number of persons reflects the full time employment falling under the scope of the register. GSK follows the guidelines provided by EFPIA regarding this registration.
Person in charge of EU relations
Person with legal responsibility
Association of the European Self-Medication Industry (AESGP)
European Brands Association (AIM)
American Chamber of Commerce to the European Union (AmChamEU)
European Biopharmaceutical Enterprises (EBE)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Vaccines Europe (VE)
World Federation of Advertisers (WFA)
Procurement from EU institutions
Grants from EU institutions
Total public financing
Other financial information
There are no notes attached to this organisation.
Expert groups (European Commission)
Intergroups (European Parliament)
Industry forums (European Parliament)
Meetings with European Commission10 meetings found.
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.
- 31 May 2018 - Annika Nowak - Brexit preparedness (DG Health)
- 23 Mar 2018 - Leila Fernandez-Stembridge - IP regime generic manufacturers in the pharmaceutical industry (DG Economics & Tax)
- 01 Dec 2017 - Maria Asenius Nele Eichhorn - FTA implementation & transparency / trade relations with China, Turkey, Russia / importance of including vaccines in trade negotiations (DG Trade)
- 09 Nov 2017 - Marika LAUTSO-MOUSNIER - Innovation in the pharmaceutical sector, SPC, health technology assessments (DG Jobs & Growth)
- 26 Jun 2017 - Commissioner Carlos Moedas - Antimicrobial resistance (AMR) (DG Research)
- 30 Sep 2015 - Paula Duarte Gaspar - Vaccination (DG Health)
- 24 Sep 2015 - Commissioner Carlos Moedas - Challenges of the pharma industry (DG Research)
- 18 May 2015 - Cécile Billaux - Access to medicines in Africa (DG Trade)
- 16 Jan 2015 - Commissioner Věra Jourová - Round Table on Gender Diversity (DG Justice)
- 05 Dec 2014 - Heidi Jern Aura Salla - Life sciences contribution to growth and jobs (DG Jobs & Growth)